Health Care • Biotechnology: Pharmaceutical Preparations
$1.81 ▼ -0.08
(-4.23%)
MKT CAP: $226.0M • VOL: 686.5K
52W L $1 52W H $6
ROARABLE / RQD
E • 29/100
PIOTROSKI
3 / 9
PYXS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $13.9M | $16.1M | $0 |
| YoY Revenue Growth % | -14.2% | — | — |
| Gross Profit | $11.5M | $15.7M | — |
| Gross Margin % | 82.8% | 97.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$84.4M | -$89.5M | -$82.2M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$79.6M | -$77.3M | -$73.8M |
| EBITDA (Normalized) | -$84.4M | -$89.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$63.5M | -$57.7M | -$70.7M |
| Capital Expenditures (CapEx) | $9.0K | $237.0K | — |
| Free Cash Flow (FCF) | -$63.5M | -$57.9M | -$70.7M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $15.4M | $19.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $53.4M | $120.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PYXS.